{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:56Z","timestamp":1793774816485,"version":"4.6.1"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,10,20]],"date-time":"2008-10-20T00:00:00Z","timestamp":1224460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This study evaluated the efficacy and safety of imatinib in chronic eosinophilic leukaemia (CEL, <jats:italic>n\u2003=\u2003<\/jats:italic>23) and hypereosinophilic syndrome (HES, <jats:italic>n\u2003=\u2003<\/jats:italic>13). In CEL with <jats:italic>FIP1L1\u2010PDGFRA<\/jats:italic> (<jats:italic>n\u2003=\u2003<\/jats:italic>16) or various <jats:italic>PDGFRB<\/jats:italic> fusion genes (<jats:italic>n\u2003=\u2003<\/jats:italic>5), complete haematological remission (CHR) was achieved in 95% (20\/21) after 3\u2003months. Complete molecular remission (CMR) was seen in 75% (12\/16) of cases with <jats:italic>FIP1L1\u2010PDGFRA<\/jats:italic> positive CEL by 6\u2003months, and in 87% (13\/15) after 12\u2003months. CMR was achieved in three of five <jats:italic>PDGFRB<\/jats:italic> fusion positive patients after 3, 9 and 18\u2003months respectively. All patients are currently on imatinib (100\u2003mg; <jats:italic>n\u2003=\u2003<\/jats:italic>13, 400\u2003mg; <jats:italic>n\u2003=\u2003<\/jats:italic>8) and no molecular relapse has yet been observed (median 26\u00b77\u2003months; range, 6\u00b79\u201339\u00b79). Imatinib was less effective in HES and CEL without known molecular aberration (<jats:italic>n\u2003=\u2003<\/jats:italic>15); CHR was observed in 40% (6\/15) of patients, two patients relapsed after 4\u00b78 and 24\u00b75\u2003months. Three patients died due to imatinib\u2010resistant progressive CEL (<jats:italic>n\u2003=\u2003<\/jats:italic>2) or myocardial infarction (<jats:italic>n\u2003=\u2003<\/jats:italic>1) unrelated to study treatment. Overall, imatinib was well tolerated with a low incidence of grade III\/IV toxicities. These data confirmed the long\u2010term efficacy of imatinib for <jats:italic>PDGFR<\/jats:italic>\u2010rearranged CEL patients, and also showed that a minority of HES cases without known molecular aberrations may benefit from imatinib.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07294.x","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T11:33:21Z","timestamp":1226403201000},"page":"707-715","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome \u2013 a phase\u2010II study"],"prefix":"10.1111","volume":"143","author":[{"given":"Georgia","family":"Metzgeroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Erben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Schmitt\u2010Graeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schnittger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grimwade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020150"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11420"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197501000-00001"},{"key":"e_1_2_6_5_1","first-page":"577B","article-title":"FIP1L1\u2010PDGFRA\u2010negative hypereosinophilic syndrome: not the usual suspects","volume":"90","author":"Cools J.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025217"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20211"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024828"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.143"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.07.013"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00652.x"},{"key":"e_1_2_6_12_1","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-050054"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0006"},{"key":"e_1_2_6_15_1","first-page":"596","article-title":"The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)\u2010FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases","volume":"90","author":"La Starza R.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404662"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1627"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0787"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.11.011"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4263"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945007779940124"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00465.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404154"},{"key":"e_1_2_6_24_1","volume-title":"An International System for Human Cytogenetic Nomenclature","author":"Shaffer L.G.","year":"2005"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06038.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03771.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403313"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10980"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07294.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07294.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T05:32:42Z","timestamp":1695965562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07294.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,11]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07294.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07294.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,11]]},"assertion":[{"value":"2008-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}